+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neuroblastoma Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 160 Pages
  • April 2024
  • Region: Global
  • Expert Market Research
  • ID: 5960380
The neuroblastoma market size is projected to grow at a compound annual growth rate (CAGR) of 2.38% during the forecast period of 2024-2032. The growth of the market is driven by the increasing incidence and prevalence of neuroblastoma, the rising awareness and funding for research and development, the availability of novel and targeted therapies, and the unmet medical needs in the field.

However, the market is also constrained by the high cost and toxicity of treatment, the lack of effective biomarkers and diagnostic tools, the heterogeneity and complexity of the disease, and the regulatory and ethical challenges in conducting clinical trials.

Neuroblastoma is a type of cancer that develops from immature nerve cells called neuroblasts. It is the most common extracranial solid tumor in children, accounting for about 7% of all pediatric cancers and 15% of all pediatric cancer deaths. The incidence of neuroblastoma is estimated to be about 11.5 cases per million children under 15 years of age, with a slight male predominance. The majority of cases (about 70%) are diagnosed before the age of 5, and about 90% before the age of 10. The prognosis of neuroblastoma varies widely depending on the age at diagnosis, the stage of the disease, the genetic and molecular features of the tumor, and the response to treatment. The 5-year survival rate ranges from over 90% for low-risk patients to less than 50% for high-risk patients.

Neuroblastoma Epidemiology

The epidemiology of neuroblastoma is influenced by several factors, such as the geographic distribution, the demographic characteristics, the environmental exposures, and the genetic and molecular variations of the disease. The epidemiology of neuroblastoma in the market can provide insights into the burden and impact of the disease, the identification of risk and protective factors, the development of prevention and screening strategies, and the estimation of the market size and potential.

The environmental exposures of neuroblastoma in the market are associated with the external and modifiable factors that can increase or decrease the risk of developing the disease. The environmental exposures of neuroblastoma in the market are not well understood and are subject to controversy and debate. However, the evidence for the role of these environmental exposures in the causation of neuroblastoma in the market is inconsistent, inconclusive, or conflicting, and requires further investigation and validation.

The genetic and molecular variations of neuroblastoma in the market are related to the internal and inherited factors that can influence the initiation, progression, and response of the disease. The genetic and molecular variations of neuroblastoma in the market are more established and recognized than the environmental exposures, and have been extensively studied and characterized. Some of the genetic and molecular variations that have been identified and validated in the pathogenesis and prognosis of neuroblastoma in the market are chromosomal aberrations, such as MYCN amplification, 1p deletion, 11q deletion, and 17q gain; gene mutations, such as ALK, PHOX2B, ATRX, and TP53; and gene expression, such as NTRK1, CD44, and NBAT1. These genetic and molecular variations of neuroblastoma in the market can be used as biomarkers and therapeutic targets and can help to stratify the patients into different risk groups and treatment protocols.

Neuroblastoma Market Drivers and Constraints

  • The increasing incidence and prevalence of neuroblastoma is a major driver for the market growth. According to the American Cancer Society (ACS), about 800 new cases of neuroblastoma are diagnosed each year in the United States, and about 10,000 new cases are diagnosed each year worldwide. The incidence of neuroblastoma has increased by about 1.8% per year over the past two decades, possibly due to improved detection and diagnosis methods. The prevalence of neuroblastoma is estimated to be about 4,000 in the United States and about 50,000 worldwide, based on the 5-year survival rate.
  • The rising awareness and funding for research and development is another key driver for the market growth. Neuroblastoma is recognized as a priority area for pediatric cancer research by several organizations and initiatives, such as the Children’s Oncology Group (COG), the International Neuroblastoma Research Group (INRG), the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), the Alex’s Lemonade Stand Foundation (ALSF), and the Neuroblastoma Children’s Cancer Society (NCCS). These entities provide support and collaboration for conducting basic, translational, and clinical research on neuroblastoma, as well as for developing and testing new and improved therapies. The National Cancer Institute (NCI) alone has invested D 100 million in neuroblastoma research in the past 10 years.
  • The availability of novel and targeted therapies is a third key driver for the market growth. The current standard of care for neuroblastoma consists of a combination of surgery, chemotherapy, radiation therapy, stem cell transplantation, and immunotherapy. However, these treatments are often associated with severe side effects, limited efficacy, and high relapse rates. Therefore, there is a need for more effective and less toxic therapies that can target the specific molecular and genetic characteristics of the tumor. Several novel and targeted therapies are in development or have been approved for neuroblastoma, such as monoclonal antibodies, tyrosine kinase inhibitors, PARP inhibitors, histone deacetylase inhibitors, and oncolytic viruses. These therapies have shown promising results in preclinical and clinical studies, and have the potential to improve the outcomes and quality of life of neuroblastoma patients.
  • The high cost and toxicity of treatment is a major constraint for the market growth. The treatment of neuroblastoma is very expensive and can impose a significant financial burden on the patients and their families. According to a study by the University of California, San Francisco (UCSF), the average cost of treating a child with high-risk neuroblastoma in the United States is D 485,000, which is more than twice the cost of treating a child with acute lymphoblastic leukemia (ALL), the most common childhood cancer. The cost of treatment can vary depending on the stage of the disease, the type and duration of therapy, the occurrence of complications and adverse events, and the availability of insurance and financial assistance. The treatment of neuroblastoma is also very toxic and can cause serious and long-term side effects, such as infections, bleeding, organ damage, growth impairment, infertility, secondary cancers, and neurocognitive deficits. These side effects can affect the physical, emotional, and social well-being of the patients and their families, and can reduce their adherence and compliance to treatment.
  • The lack of effective biomarkers and diagnostic tools is another major constraint for the market growth. The diagnosis and prognosis of neuroblastoma are challenging and rely on a combination of clinical, radiological, histological, and molecular criteria. However, these criteria are not always accurate, consistent, or available, and can lead to misdiagnosis, underdiagnosis, or overdiagnosis of the disease. There is a need for more reliable and accessible biomarkers and diagnostic tools that can detect neuroblastoma early, predict the risk and outcome of the disease, monitor the response and resistance to treatment, and identify the patients who are most likely to benefit from specific therapies. Several biomarkers and diagnostic tools are under investigation or have been validated for neuroblastoma, such as urine catecholamines, serum ferritin, MYCN amplification, ALK mutations, and PET/CT scans. However, these biomarkers and diagnostic tools are not widely used in clinical practice, and their sensitivity, specificity, and utility need to be further evaluated and standardized.

Neuroblastoma Market Trends and Developments

The global neuroblastoma market is witnessing a significant evolution, driven by advances in medical research, technological innovations, and an increasing emphasis on personalized medicine. Neuroblastoma, a type of cancer that most often affects children and is characterized by tumors that develop from immature nerve cells, has been the focus of intense research efforts aimed at improving diagnosis, treatment, and survival rates. Several key trends and developments have emerged in this market such as:

1. Advances in Targeted Therapies

The development of targeted therapies represents a major advancement in the treatment of neuroblastoma. These therapies are designed to specifically attack cancer cells based on genetic characteristics without harming normal cells. The use of molecular targeted agents, such as ALK inhibitors and GD2-targeted therapies, has shown promise in improving outcomes for patients with high-risk neuroblastoma. The precision of these treatments not only enhances efficacy but also minimizes side effects, a critical consideration in pediatric oncology.

2. Immunotherapy Breakthroughs

Immunotherapy, leveraging the body's immune system to fight cancer, has made significant inroads in the neuroblastoma market. The approval and use of monoclonal antibodies, such as dinutuximab that targets GD2 on neuroblastoma cells, have markedly improved survival rates for high-risk patients. Ongoing research into novel immune checkpoint inhibitors and CAR-T cell therapies is expected to offer new hope for refractory or relapsed neuroblastoma cases.

3. Diagnostic and Prognostic Biomarkers

The identification and validation of biomarkers for neuroblastoma have enhanced both diagnostic and prognostic capabilities. Advanced genetic testing and imaging technologies enable early and accurate diagnosis of the disease, which is critical for effective treatment planning. Biomarkers are also being used to stratify patients according to risk, allowing for more tailored treatment approaches that can improve outcomes and reduce toxicity.

4. Rising Focus on Survivorship and Quality of Life

As survival rates for neuroblastoma improve, there is a growing emphasis on the long-term health and quality of life of survivors. Research is increasingly focusing on understanding and mitigating the late effects of neuroblastoma treatments, including secondary cancers, cardiovascular problems, and developmental issues. Efforts are also being made to develop interventions that support the emotional and psychological well-being of both patients and their families.

5. Increased Investment in Research and Collaboration

The neuroblastoma market is benefiting from increased investment in research and development, fueled by both public and private funding. Collaborations between pharmaceutical companies, academic institutions, and nonprofit organizations are accelerating the pace of innovation in treatment and care. These partnerships are crucial for conducting large-scale clinical trials, sharing knowledge, and translating research findings into clinical practice.

The global neuroblastoma market is at a pivotal juncture, with significant advancements in treatment and care reshaping the landscape. The focus on targeted and immunotherapeutic approaches, along with the integration of biomarkers for personalized medicine, is setting new standards in pediatric oncology. Moreover, the attention to survivorship issues underscores a holistic approach to cancer care that balances treatment efficacy with quality of life considerations. As research and collaboration continue to drive forward, the prospects for patients with neuroblastoma are brighter than ever.

Neuroblastoma Market Segmentation

Market Breakup by Diagnosis

  • MIBG Scan
  • Imaging
  • Biopsy

Market Breakup by Treatment

  • Medication
  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Stem Cell Transplantation
  • Immunotherapy
  • Monoclonal Antibody Treatment

Market Breakup by Age Group

  • Infants
  • Children
  • Adolescents

Market Breakup by End User

  • Hospitals
  • Specialty Clinics
  • Surgical Centers
  • Diagnostic Centers
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • China

Neuroblastoma Market Competitor Landscape

The competitive landscape of the global neuroblastoma market is characterized by the active participation of major pharmaceutical and biotechnology companies, alongside key players in diagnostics and biologics. These entities are engaged in a variety of market activities, including mergers and acquisitions, collaborative research initiatives, the introduction of new products, and strategic partnerships aimed at advancing neuroblastoma treatment and diagnostic solutions. Key players in this dynamic market include Eli Lilly and Company, Bayer AG, GE Healthcare, Beckman Coulter Inc., bioMerieux, BD Biosciences, Lonza Biologics Ltd., Sanofi S.A., Pfizer Inc., Cellectar Biosciences, Baxter International Inc., APEIRON Biologics AG, United Therapeutics Corporation, Sartorious AG, and MacroGenics, Inc. These companies are at the forefront of innovation in neuroblastoma care, driving progress through extensive research and development efforts, as well as through forging alliances and exploring synergies that can enhance treatment efficacy and improve patient outcomes.


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Neuroblastoma Market Overview -8 Major Markets
3.1 Neuroblastoma Market Historical Value (2017-2023)
3.2 Neuroblastoma Market Forecast Value (2024-2032)
4 Neuroblastoma Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Therapy Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Therapy Success Rate
6 Neuroblastoma Epidemiology Analysis- 8 Major Markets
6.1 Epidemiology Overview (2017-2032)
6.2 8 Major Markets Epidemiology Scenario Overview (2017-2032)
6.3 United States Neuroblastoma Epidemiology Forecast (2017-2032)
6.4 EU-4 and United Kingdom Neuroblastoma Epidemiology Forecast (2017-2032)
6.4.1 Germany Neuroblastoma Epidemiology Forecast (2017-2032)
6.4.2 France Neuroblastoma Epidemiology Forecast (2017-2032)
6.4.3 Italy Neuroblastoma Epidemiology Forecast (2017-2032)
6.4.4 Spain Neuroblastoma Epidemiology Forecast (2017-2032)
6.4.5 United Kingdom Neuroblastoma Epidemiology Forecast (2017-2032)
6.5 Japan Neuroblastoma Epidemiology Forecast (2017-2032)
6.6 China Neuroblastoma Epidemiology Forecast (2017-2032)
7 Neuroblastoma Market Landscape* - 8 Major Markets
7.1 Neuroblastoma Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Neuroblastoma Product Landscape
7.2.1 Analysis by Diagnosis
7.2.2 Analysis by Treatment
8 Neuroblastoma Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Neuroblastoma Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 SWOT Analysis
10.3.1 Strengths
10.3.2 Weaknesses
10.3.3 Opportunities
10.3.4 Threats
10.4 Porter’s Five Forces Model
10.4.1 Bargaining Power of Suppliers
10.4.2 Bargaining Power of Buyers
10.4.3 Threat of New Entrants
10.4.4 Threat of Substitutes
10.4.5 Degree of Rivalry
10.5 Key Demand Indicators
10.6 Key Price Indicators
10.7 Industry Events, Initiatives, and Trends
10.8 Value Chain Analysis
11 Neuroblastoma Market (2017-2032) Segmentation-8 Major Markets
11.1 Neuroblastoma Market (2017-2032) by Diagnosis
11.1.1 Market Overview
11.1.2 MIBG Scan
11.1.3 Imaging
11.1.4 Biopsy
11.2 Neuroblastoma Market (2017-2032) by Treatment
11.2.1 Market Overview
11.2.2 Medication
11.2.3 Surgery
11.2.4 Chemotherapy
11.2.5 Radiation Therapy
11.2.6 Stem Cell Transplantation
11.2.7 Immunotherapy
11.2.8 Monoclonal Antibody Treatment
11.3 Neuroblastoma Market (2017-2032) by Age Group
11.3.1 Market Overview
11.3.2 Infants
11.3.3 Children
11.3.4 Adolescents
11.4 Neuroblastoma Market (2017-2032) by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Specialty Clinics
11.4.4 Surgical Centers
11.4.5 Diagnostic Centers
11.4.6 Others
11.5 Neuroblastoma Market (2017-2032) by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
11.5.5 China
12 United States Neuroblastoma Market (2017-2032)
12.1 United States Neuroblastoma Market Historical Value (2017-2023)
12.2 United States Neuroblastoma Market Forecast Value (2024-2032)
12.3 United States Neuroblastoma Market (2017-2032) by Diagnosis
12.3.1 Market Overview
12.3.2 MIBG Scan
12.3.3 Imaging
12.3.4 Biopsy
12.4 United States Neuroblastoma Market (2017-2032) by Treatment
12.4.1 Market Overview
12.4.2 Medication
12.4.3 Surgery
12.4.4 Chemotherapy
12.4.5 Radiation Therapy
12.4.6 Stem cell transplantation
12.4.7 Immunotherapy
12.4.8 Monoclonal Antibody Treatment
13 EU-4 and United Kingdom Neuroblastoma Market (2017-2032)
13.1 EU-4 and United Kingdom Neuroblastoma Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Neuroblastoma Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Neuroblastoma Market (2017-2032) by Diagnosis
13.3.1 Market Overview
13.3.2 MIBG Scan
13.3.3 Imaging
13.3.4 Biopsy
13.4 EU-4 and United Kingdom Neuroblastoma Market (2017-2032) by Treatment
13.4.1 Market Overview
13.4.2 Medication
13.4.3 Surgery
13.4.4 Chemotherapy
13.4.5 Radiation Therapy
13.4.6 Stem cell transplantation
13.4.7 Immunotherapy
13.4.8 Monoclonal Antibody Treatment
14 Japan Neuroblastoma Market (2017-2032)
14.1 Japan Neuroblastoma Market Historical Value (2017-2023)
14.2 Japan Neuroblastoma Market Forecast Value (2024-2032)
14.3 Japan Neuroblastoma Market (2017-2032) by Diagnosis
14.3.1 Market Overview
14.3.2 MIBG Scan
14.3.3 Imaging
14.3.4 Biopsy
14.4 Japan Neuroblastoma Market (2017-2032) by Treatment
14.4.1 Market Overview
14.4.2 Medication
14.4.3 Surgery
14.4.4 Chemotherapy
14.4.5 Radiation Therapy
14.4.6 Stem cell transplantation
14.4.7 Immunotherapy
14.4.8 Monoclonal Antibody Treatment
15 China Neuroblastoma Market (2017-2032)
15.1 China Neuroblastoma Market Historical Value (2017-2023)
15.2 China Neuroblastoma Market Forecast Value (2024-2032)
15.3 China Neuroblastoma Market (2017-2032) by Diagnosis
15.3.1 Market Overview
15.3.2 MIBG Scan
15.3.3 Imaging
15.3.4 Biopsy
15.4 China Neuroblastoma Market (2017-2032) by Treatment
15.4.1 Market Overview
15.4.2 Medication
15.4.3 Surgery
15.4.4 Chemotherapy
15.4.5 Radiation Therapy
15.4.6 Stem cell transplantation
15.4.7 Immunotherapy
15.4.8 Monoclonal Antibody Treatment
16 Regulatory Framework
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 JAPAN PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaboration Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Eli Lilly and Company
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 Bayer AG
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 GE Healthcare
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Beckman Coulter Inc
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 bioMerieux
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 BD Biosciences
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 Lonza Biologics Ltd
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Sanofi S.A.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Pfizer Inc.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Cellectar Biosciences
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Baxter International Inc.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 APEIRON Biologics AG
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 United Therapeutics Corporation
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
22.14 Sartorious AG
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisition
22.14.5 Certifications
22.15 MacroGenics, Inc.
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisition
22.15.5 Certifications
23 Neuroblastoma Market - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The research team strives to make this section as comprehensive as possible.

Companies Mentioned

  • Eli Lilly and Company
  • Bayer AG
  • GE Healthcare
  • Beckman Coulter Inc
  • bioMerieux
  • BD Biosciences
  • Lonza Biologics Ltd Sanofi S.A.
  • Pfizer Inc.
  • Cellectar Biosciences
  • Baxter International Inc.
  • APEIRON Biologics AG
  • United Therapeutics Corporation
  • Sartorious AG
  • MacroGenics Inc.

Methodology

Loading
LOADING...